Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
138 hedge funds and large institutions have $833M invested in Epizyme, Inc in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 41 reducing their positions, and 15 closing their positions.
926% more call options, than puts
Call options by funds: $22.3M | Put options by funds: $2.17M
27% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 41
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
0% more funds holding
Funds holding: 138 → 138 (0)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20% less capital invested
Capital invested by funds: $1.05B → $833M (-$212M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$14M |
| 2 |
BlackRock
New York
|
+$4.98M |
| 3 |
Millennium Management
New York
|
+$4.41M |
| 4 |
Two Sigma Investments
New York
|
+$3.69M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$27.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.57M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$6.48M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.23M |
| 5 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
-$3.79M |
EPZM Hedge Fund Activity: Q1 2021 in Review
138 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2021, worth a combined $833M — down 20% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new EPZM positions and 15 closed out — a net gain of 3 holders — while 52 added to existing stakes and 41 trimmed.
The largest buyer was State Street, adding an estimated $14M. The largest seller was Victory Capital Management, cutting an estimated $27.5M.
- 138 institutional investors held Epizyme, Inc (EPZM) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $833M of Epizyme, Inc stock for Q1 2021, down 20% quarter-over-quarter.
- 18 funds opened new Epizyme, Inc positions in Q1 2021 and 15 closed out, a net change of +3 holders.
- The largest Epizyme, Inc buyer in Q1 2021 was State Street, an estimated $14M added.
- The largest Epizyme, Inc seller in Q1 2021 was Victory Capital Management, an estimated $27.5M sold.
Based on aggregated 13F filings for Q1 2021.